Phase 1 Stomach Cancer Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have been diagnosed with a type of blood cancer called a mature B-cell malignancy, confirmed through a lab test on a tissue or cell sample.
- People who have a measurable or detectable amount of disease, based on the standard assessment system for their specific condition, and whose disease has reached a point where treatment would normally be started.
- People who are largely able to carry out daily activities with little or no restriction (this is measured using a standard scale called ECOG, where a score of 0 means fully active and 1 means slightly limited).
- People who are expected to live for at least 12 weeks or more.
Who may not be able to join:
- People who need urgent, rapid treatment to reduce the amount of cancer in their body right away — unless there are no other remaining treatment options that could help.
- People who have had another type of invasive cancer within the last 2 years.
- People who have a known allergy to the trial drug SGR-1505 or any of its ingredients.
- People whose cancer has spread to, or is actively affecting, the brain or spinal cord in a way that is causing symptoms.
- People who have any other health condition, abnormal test result, or physical finding that the trial site determines could put them at increased risk from taking an investigational (experimental) drug (confirm with trial site).
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Frank G Basile, M.D., Schrodinger Inc.
Phone: +1 (503)-922-0158
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Nature, severity, and number of incidences of adverse events (AEs), serious AEs (SAEs), and AEs leading to treatment discontinuation.; Nature and number of incidences of dose limiting toxicity (DLT).
Can't join this trial?
Data last synced from ClinicalTrials.gov: 19 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.